Spots Global Cancer Trial Database for renal carcinoma
Every month we try and update this database with for renal carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | NCT03638206 | B-cell Acute Ly... Lymphoma Myeloid Leukemi... Multiple Myelom... Hepatoma Gastric Cancer Pancreatic Canc... Mesothelioma Colorectal Canc... Esophagus Cance... Lung Cancer Glioma Melanoma Synovial Sarcom... Ovarian Cancer Renal Carcinoma | CAR-T cell immu... | 4 Years - 70 Years | Shenzhen BinDeBio Ltd. | |
| An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037 | NCT00884520 | Lung Cancer Squamous Cell C... Head and Neck C... Hepatic Carcino... Renal Cell Carc... | [F-18] VM4-037 | 18 Years - | Siemens Molecular Imaging | |
| Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | NCT06318871 | Renal Carcinoma Renal Cell Carc... Urothelial Carc... | Cytokine Induce... N-803 | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations | NCT03786796 | Renal Cell Carc... Metastatic Rena... Kidney Cancer Renal Carcinoma Kidney Cancer M... | Olaparib | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma | NCT00729053 | Renal Cell Carc... | IMO-2055 | 18 Years - | Idera Pharmaceuticals, Inc. | |
| Rotating Pazopanib and Everolimus to Avoid Resistance | NCT01408004 | Clear Cell Rena... | Pazopanib Everolimus Pazopanib Everolimus Everolimus Pazopanib | 18 Years - | Netherlands Working Group on Immunotherapy of Oncology | |
| Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium | NCT02928692 | Prostate Cancer Carcinoma of th... Colon Cancer Renal Carcinoma | Minocycline Placebo | 65 Years - | RenJi Hospital | |
| Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K) | NCT06290427 | Renal Carcinoma | DaVinci RAPN Hugo RAS RAPN Versius® RAPN | 18 Years - 90 Years | Azienda Ospedaliera Universitaria Integrata Verona | |
| Rotating Pazopanib and Everolimus to Avoid Resistance | NCT01408004 | Clear Cell Rena... | Pazopanib Everolimus Pazopanib Everolimus Everolimus Pazopanib | 18 Years - | Netherlands Working Group on Immunotherapy of Oncology | |
| Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma | NCT01342627 | Metastatic Rena... | Sorafenib | 65 Years - | Centro di Riferimento Oncologico - Aviano | |
| A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors | NCT04773951 | Melanoma Renal Carcinoma Urothelial Carc... | JS004, a recomb... | 18 Years - 70 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR) | NCT05456074 | Renal Carcinoma | Data collection | - | Institut de cancérologie Strasbourg Europe | |
| Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium | NCT02928692 | Prostate Cancer Carcinoma of th... Colon Cancer Renal Carcinoma | Minocycline Placebo | 65 Years - | RenJi Hospital | |
| Rotating Pazopanib and Everolimus to Avoid Resistance | NCT01408004 | Clear Cell Rena... | Pazopanib Everolimus Pazopanib Everolimus Everolimus Pazopanib | 18 Years - | Netherlands Working Group on Immunotherapy of Oncology | |
| A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies | NCT00441337 | Carcinoma, Non-... Colorectal Canc... Malignant Melan... Renal Cancer Prostate Cancer | MDX-1106 | 18 Years - | Bristol-Myers Squibb | |
| A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors | NCT04773951 | Melanoma Renal Carcinoma Urothelial Carc... | JS004, a recomb... | 18 Years - 70 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients | NCT03114826 | Polymorphism VEGF Renal Carcinoma Renal Transplan... | To study the po... | 18 Years - | Centre Hospitalier Universitaire, Amiens | |
| Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations | NCT03786796 | Renal Cell Carc... Metastatic Rena... Kidney Cancer Renal Carcinoma Kidney Cancer M... | Olaparib | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
